Developer docs
API playgroundTry for free, no card

Search company profiles

panCELLa

Full company profile

uuid00048ry

Namestring
panCELLa
Websiteurl
pancella.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

panCELLa is a privately held biotechnology company headquartered in Mississauga, in the Greater Toronto Area of Canada, founded in 2015. The company's described technical focus is on induced pluripotent stem cell (iPSC)-derived cell therapeutics, leveraging CRISPR-based gene editing applied to iPSC lines as its core platform. The leadership reflects a scientific-founder orientation: Andras Nagy serves as Founder, President and Chief Scientific Officer, bringing a stem cell biology research background, and Armand Keating serves as Founder and Chief Medical Officer, contributing hematology expertise. Mahendra Rao serves as Chief Executive Officer and Greg Hood as Chief Operating Officer, providing operational and corporate leadership around the founding scientific team. Headcount is reported at 1–10 employees, consistent with a lean, research-led organization.

The technical architecture implied by the firm's positioning combines iPSC reprogramming methodology with CRISPR-mediated gene editing — a platform used by a small set of competitors to engineer immune-evasive or disease-corrected cell lines for therapeutic application. No specific product candidates, indications, or pipeline stages are disclosed in the input, and no patents, trademarks, or regulatory actions are listed. The company maintains a corporate website (https://pancella.com/) but no product details, customer references, partnerships, or integration data are provided in the source material.

panCELLa's business model is preclinical and not yet revenue-generating based on the available evidence. The only disclosed capital event is a $1.0 million equity raise on 2018-01-24 from Chiefswood Holdings Limited. No customers, distribution channels, pricing models, or licensing arrangements appear in the input, indicating the firm is currently operating in a research and development phase rather than a commercial revenue phase. The absence of disclosed subsequent funding rounds in the source material limits visibility into the firm's current capitalization and runway position.

Short descriptiontext

panCELLa is a Toronto-area biotechnology company founded in 2015 that develops iPSC-derived cell therapeutics using CRISPR gene editing, operated by a small team of stem cell research founders.

Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
cell therapy platforms, regenerative medicine, stem cell therapeutics, CRISPR gene editing, iPSC technology
Industry3 codes
PRIMARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
Product category
Cell Therapy & Regenerative Medicine
Social media profiles1 record
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

panCELLa is a Toronto-area biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapeutics and CRISPR-based gene editing platforms. The company focuses on regenerative medicine applications, leveraging proprietary cell engineering technologies to create therapeutic cell products for clinical and research use. Its work spans cell therapy platform development for treating diseases using engineered stem cell-derived products.

Differentiator
Functional benefit
Problem solved
Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

Toronto-based Centre for Commercialization of Regenerative Medicine — a developer and manufacturer of cell and gene therapies. Not a direct competitor, but a key infrastructure partner and ecosystem peer for Toronto-based cell therapy companies like panCELLa.

TypeDirect peer
Description

Bayer-owned iPSC-derived cell therapy developer focused on regenerative medicine for neurology, cardiology, and immunology. Highly comparable given panCELLa's iPSC and regenerative-medicine orientation, though materially better capitalized.

TypeDirect peer
Description

Clinical-stage iPSC-derived allogeneic cell therapy developer using gene editing (including CRISPR) to engineer immune cells. Closely mirrors panCELLa's iPSC + CRISPR platform positioning.

TypeDirect peer
Description

Pioneer in iPSC-derived cell therapies, with multiple clinical-stage NK and T-cell programs. A clear benchmark for the category panCELLa is operating in.

5Notch Therapeutics
TypeDirect peer
Description

Toronto-based iPSC-derived T-cell therapy developer with programs in oncology. Highly comparable as both a Canadian iPSC cell therapy peer and a regional competitor.

6ViaCyte
TypeDirect peer
Description

Stem cell-derived cell therapy developer focused on regenerative medicine for diabetes. Comparable as a peer in pluripotent stem cell-derived therapeutics.

7Aspect Biosystems
TypeRegional player
Description

Vancouver-based biotechnology company developing cell therapies using proprietary bioprinting and stem cell technologies. Comparable as a Canadian regenerative-medicine cell therapy peer with platform-level ambitions.

TypeBroad incumbent
Description

Clinical-stage cell and gene therapy company with programs spanning iPSC-derived cells, in vivo gene delivery, and ex vivo engineering. Broader platform than panCELLa but operates in the same iPSC + gene editing frontier.

TypeBroad incumbent
Description

Clinical-stage allogeneic CAR-T developer pioneering off-the-shelf cell therapies. Comparable as a benchmark allogeneic cell therapy player in the broader category panCELLa addresses.

TypeEmerging player
Description

Clinical-stage cell therapy company engineering NK cells for cancer and autoimmune disease. Comparable as a peer in next-generation engineered cell therapy with comparable size and stage profile.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

panCELLa

Cell Therapy & Regenerative Medicinepancella.com

panCELLa is a Toronto-area biotechnology company founded in 2015 that develops iPSC-derived cell therapeutics using CRISPR gene editing, operated by a small team of stem cell research founders.

What panCELLa does

panCELLa is a privately held biotechnology company headquartered in Mississauga, in the Greater Toronto Area of Canada, founded in 2015. The company's described technical focus is on induced pluripotent stem cell (iPSC)-derived cell therapeutics, leveraging CRISPR-based gene editing applied to iPSC lines as its core platform. The leadership reflects a scientific-founder orientation: Andras Nagy serves as Founder, President and Chief Scientific Officer, bringing a stem cell biology research background, and Armand Keating serves as Founder and Chief Medical Officer, contributing hematology expertise. Mahendra Rao serves as Chief Executive Officer and Greg Hood as Chief Operating Officer, providing operational and corporate leadership around the founding scientific team. Headcount is reported at 1–10 employees, consistent with a lean, research-led organization.

The technical architecture implied by the firm's positioning combines iPSC reprogramming methodology with CRISPR-mediated gene editing — a platform used by a small set of competitors to engineer immune-evasive or disease-corrected cell lines for therapeutic application. No specific product candidates, indications, or pipeline stages are disclosed in the input, and no patents, trademarks, or regulatory actions are listed. The company maintains a corporate website (https://pancella.com/) but no product details, customer references, partnerships, or integration data are provided in the source material.

panCELLa's business model is preclinical and not yet revenue-generating based on the available evidence. The only disclosed capital event is a $1.0 million equity raise on 2018-01-24 from Chiefswood Holdings Limited. No customers, distribution channels, pricing models, or licensing arrangements appear in the input, indicating the firm is currently operating in a research and development phase rather than a commercial revenue phase. The absence of disclosed subsequent funding rounds in the source material limits visibility into the firm's current capitalization and runway position.

panCELLa firmographics

Firmographics
Name
panCELLa
Website
https://pancella.com
Company type
Private
Founded year
2015
Headcount range
11–50 employees
Short description
panCELLa is a Toronto-area biotechnology company founded in 2015 that develops iPSC-derived cell therapeutics using CRISPR gene editing, operated by a small team of stem cell research founders.
Ownership category
akta.pro rank

panCELLa industry classification

Industry
Product category
Cell Therapy & Regenerative Medicine
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
akta.pro industry
PRIMARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Cell therapy platforms
  • Regenerative medicine
  • Stem cell therapeutics
  • CRISPR gene editing
  • IPSC technology

Where panCELLa is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Markets served

panCELLa business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations

panCELLa product offering

Product offering

Core offering

panCELLa is a Toronto-area biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapeutics and CRISPR-based gene editing platforms. The company focuses on regenerative medicine applications, leveraging proprietary cell engineering technologies to create therapeutic cell products for clinical and research use. Its work spans cell therapy platform development for treating diseases using engineered stem cell-derived products.

Differentiator

Problem solved

Functional benefit

Companies that use panCELLa

Customer profile

Ideal customer profiles1 record

panCELLa technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

panCELLa partnerships and signals

Strategic signal

Recent moves4 records

Expansion highlights2 records

panCELLa competitors and assessment

Company assessment

Others

  • CCRM: Toronto-based Centre for Commercialization of Regenerative Medicine — a developer and manufacturer of cell and gene therapies. Not a direct competitor, but a key infrastructure partner and ecosystem peer for Toronto-based cell therapy companies like panCELLa.

Direct peers

  • BlueRock Therapeutics: Bayer-owned iPSC-derived cell therapy developer focused on regenerative medicine for neurology, cardiology, and immunology. Highly comparable given panCELLa's iPSC and regenerative-medicine orientation, though materially better capitalized.
  • Century Therapeutics: Clinical-stage iPSC-derived allogeneic cell therapy developer using gene editing (including CRISPR) to engineer immune cells. Closely mirrors panCELLa's iPSC + CRISPR platform positioning.
  • Fate Therapeutics: Pioneer in iPSC-derived cell therapies, with multiple clinical-stage NK and T-cell programs. A clear benchmark for the category panCELLa is operating in.
  • Notch Therapeutics: Toronto-based iPSC-derived T-cell therapy developer with programs in oncology. Highly comparable as both a Canadian iPSC cell therapy peer and a regional competitor.
  • ViaCyte: Stem cell-derived cell therapy developer focused on regenerative medicine for diabetes. Comparable as a peer in pluripotent stem cell-derived therapeutics.

Regional players

  • Aspect Biosystems: Vancouver-based biotechnology company developing cell therapies using proprietary bioprinting and stem cell technologies. Comparable as a Canadian regenerative-medicine cell therapy peer with platform-level ambitions.

Broad incumbents

  • Sana Biotechnology: Clinical-stage cell and gene therapy company with programs spanning iPSC-derived cells, in vivo gene delivery, and ex vivo engineering. Broader platform than panCELLa but operates in the same iPSC + gene editing frontier.
  • Allogene Therapeutics: Clinical-stage allogeneic CAR-T developer pioneering off-the-shelf cell therapies. Comparable as a benchmark allogeneic cell therapy player in the broader category panCELLa addresses.

Emerging players

  • Nkarta: Clinical-stage cell therapy company engineering NK cells for cancer and autoimmune disease. Comparable as a peer in next-generation engineered cell therapy with comparable size and stage profile.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

panCELLa social profiles

Digital presence

panCELLa financial estimates

Financial estimate

Revenue estimate

Valuation estimate

panCELLa leadership team

Management profile

Number of profiles

Profiles4 records

panCELLa funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

panCELLa M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about panCELLa

What does panCELLa do?

panCELLa is a Toronto-area biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapeutics and CRISPR-based gene editing platforms. The company focuses on regenerative medicine applications, leveraging proprietary cell engineering technologies to create therapeutic cell products for clinical and research use. Its work spans cell therapy platform development for treating diseases using engineered stem cell-derived products.

Is panCELLa a public or private company?

panCELLa is a private company. It is classified as venture growth investor backed.

When was panCELLa founded?

panCELLa was founded in 2015. It employs 11 to 50 people.

Where is panCELLa based?

panCELLa is headquartered in Toronto, Canada, in the North America region.

Who are panCELLa's main competitors?

CCRM is listed as an others. Direct peers are BlueRock Therapeutics, Century Therapeutics, Fate Therapeutics, Notch Therapeutics and ViaCyte. Aspect Biosystems is listed as a regional player. Broad incumbents are Sana Biotechnology and Allogene Therapeutics. Nkarta is listed as an emerging player.

Does panCELLa have an API?

No public API is recorded for panCELLa.

What industry is panCELLa in?

panCELLa's product category is Cell Therapy & Regenerative Medicine. Its primary akta.pro industry code is HLAAABAA, Cell Therapy Developers (Autologous), with a secondary code of HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 325414.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals